Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

NCT03699384 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study sponsor discontinued support

Conditions

Acute Myeloid Leukemia (AML)
Minimal Residual Disease

Interventions

DRUG: Azacitidine
DRUG: Avelumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]